Loading…
Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial
Synovial fluid in patients may differ in molecular weight depending on the presence and degree of osteoarthritis. Treatment is not directed at this relationship. Patients with osteoarthritis of the knee with resting visual analogue scale (VAS) pain of >45 mm were included in a randomized, prospec...
Saved in:
| Published in: | Clinical rheumatology 2008-08, Vol.27 (8), p.975-981 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c369t-31eacc41e9a624dc8b929bd42faa5b1482ac68e709e3de17059aa54a1268d66e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c369t-31eacc41e9a624dc8b929bd42faa5b1482ac68e709e3de17059aa54a1268d66e3 |
| container_end_page | 981 |
| container_issue | 8 |
| container_start_page | 975 |
| container_title | Clinical rheumatology |
| container_volume | 27 |
| creator | Petrella, Robert J. Cogliano, Anthony Decaria, Joseph |
| description | Synovial fluid in patients may differ in molecular weight depending on the presence and degree of osteoarthritis. Treatment is not directed at this relationship. Patients with osteoarthritis of the knee with resting visual analogue scale (VAS) pain of >45 mm were included in a randomized, prospective, double-blind cohort followed for 16 weeks. Patients were randomized at baseline to receive a three intra-articular injection series with one of: dual molecular weight (DMW; 580–780 kDa + 1.2 to 2.0 million Da); low molecular weight (LMW; 500–730 kDa); high molecular weight (HMW; 6 million Da); or saline placebo over 3 weeks. Patients completed baseline assessment of rest and walking VAS pain (primary efficacy variable), collection of a 5-point categorical global satisfaction score, and record of adverse events. Two-hundred and twenty-five patients (age 68 ± 8 y) were screened and 200 were randomized to one of the four groups. There were no differences at baseline between groups. At 4, 12 and 16 weeks, respectively, walking VAS pain was significantly improved in all treatment groups vs. placebo: DMW (79.6%,
p
|
| doi_str_mv | 10.1007/s10067-007-0834-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69282825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2418588621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-31eacc41e9a624dc8b929bd42faa5b1482ac68e709e3de17059aa54a1268d66e3</originalsourceid><addsrcrecordid>eNp1kdFLZCEUxiVaamr3D9iXkB566pZ6nXu1txh2Kwj2pZ7Fq2caW69O6iXqr89hBoIgBP3k_M7nwQ-h35RcUEL6y1z3rm-qbIhoecP30IzyKqTkch_NSN-TpqVSHKKjnJ8JIUxIeoAOqWCEi76dobSI4-CCC0-4vEa8etN-SjE4g7VxNmMXcMwFok5llVxxGcclLivA_wPAFdY46WDj6N7BnmMbp8FDM3gX6m3ttYEhNiaGkqL3YHFJTvuf6MdS-wy_ducxevz752Fx29z_u7lbXN83pu1kqXODNoZTkLpj3BoxSCYHy9lS6_lAuWDadAJ6IqG1QHsyl7XANWWdsF0H7TE62_quU3yZIBc1umzAex0gTll1kom65hU8_QI-xymFOpsSgraCzAmrEN1CJsWcEyzVOrlRpzdFidqkobZpqI3cpKF47TnZGU_DCPazY_f9FWBbINdSeIL0-fL3rh9D_ZYP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881380502</pqid></control><display><type>article</type><title>Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial</title><source>Springer Nature</source><creator>Petrella, Robert J. ; Cogliano, Anthony ; Decaria, Joseph</creator><creatorcontrib>Petrella, Robert J. ; Cogliano, Anthony ; Decaria, Joseph</creatorcontrib><description><![CDATA[Synovial fluid in patients may differ in molecular weight depending on the presence and degree of osteoarthritis. Treatment is not directed at this relationship. Patients with osteoarthritis of the knee with resting visual analogue scale (VAS) pain of >45 mm were included in a randomized, prospective, double-blind cohort followed for 16 weeks. Patients were randomized at baseline to receive a three intra-articular injection series with one of: dual molecular weight (DMW; 580–780 kDa + 1.2 to 2.0 million Da); low molecular weight (LMW; 500–730 kDa); high molecular weight (HMW; 6 million Da); or saline placebo over 3 weeks. Patients completed baseline assessment of rest and walking VAS pain (primary efficacy variable), collection of a 5-point categorical global satisfaction score, and record of adverse events. Two-hundred and twenty-five patients (age 68 ± 8 y) were screened and 200 were randomized to one of the four groups. There were no differences at baseline between groups. At 4, 12 and 16 weeks, respectively, walking VAS pain was significantly improved in all treatment groups vs. placebo: DMW (79.6%,
p
< 0.001; 85.6,
p
< 0.001; 89.3%,
p
< 0.001); LMW (73.6%,
p
< 0.001; 76.4,
p
< 0.001; 81.3%,
p
< 0.001) and HMW (69.1%,
p
< 0.001; 81.0,
p
< 0.001; 79.1%,
p
< 0.001). Patients in the DMW group had significantly greater improvement (
p
< 0.007) in VAS walking pain by 3 weeks (following the second injection) compared to all groups. This difference was persistent at 16 weeks. Greater improvement in patients who received the DMW product was achieved by the second injection persistent at 16 weeks.]]></description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-007-0834-4</identifier><identifier>PMID: 18204873</identifier><language>eng</language><publisher>London: Springer-Verlag</publisher><subject>Aged ; Aged, 80 and over ; Arthritis ; Dietary supplements ; Double-Blind Method ; Female ; Humans ; Hyaluronic Acid - chemistry ; Hyaluronic Acid - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Molecular weight ; Original Article ; Osteoarthritis, Knee - drug therapy ; Pain ; Pain - drug therapy ; Pain Measurement ; Prospective Studies ; Rheumatology ; Viscosupplements - chemistry ; Viscosupplements - therapeutic use</subject><ispartof>Clinical rheumatology, 2008-08, Vol.27 (8), p.975-981</ispartof><rights>Clinical Rheumatology 2007</rights><rights>Clinical Rheumatology 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-31eacc41e9a624dc8b929bd42faa5b1482ac68e709e3de17059aa54a1268d66e3</citedby><cites>FETCH-LOGICAL-c369t-31eacc41e9a624dc8b929bd42faa5b1482ac68e709e3de17059aa54a1268d66e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18204873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Petrella, Robert J.</creatorcontrib><creatorcontrib>Cogliano, Anthony</creatorcontrib><creatorcontrib>Decaria, Joseph</creatorcontrib><title>Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description><![CDATA[Synovial fluid in patients may differ in molecular weight depending on the presence and degree of osteoarthritis. Treatment is not directed at this relationship. Patients with osteoarthritis of the knee with resting visual analogue scale (VAS) pain of >45 mm were included in a randomized, prospective, double-blind cohort followed for 16 weeks. Patients were randomized at baseline to receive a three intra-articular injection series with one of: dual molecular weight (DMW; 580–780 kDa + 1.2 to 2.0 million Da); low molecular weight (LMW; 500–730 kDa); high molecular weight (HMW; 6 million Da); or saline placebo over 3 weeks. Patients completed baseline assessment of rest and walking VAS pain (primary efficacy variable), collection of a 5-point categorical global satisfaction score, and record of adverse events. Two-hundred and twenty-five patients (age 68 ± 8 y) were screened and 200 were randomized to one of the four groups. There were no differences at baseline between groups. At 4, 12 and 16 weeks, respectively, walking VAS pain was significantly improved in all treatment groups vs. placebo: DMW (79.6%,
p
< 0.001; 85.6,
p
< 0.001; 89.3%,
p
< 0.001); LMW (73.6%,
p
< 0.001; 76.4,
p
< 0.001; 81.3%,
p
< 0.001) and HMW (69.1%,
p
< 0.001; 81.0,
p
< 0.001; 79.1%,
p
< 0.001). Patients in the DMW group had significantly greater improvement (
p
< 0.007) in VAS walking pain by 3 weeks (following the second injection) compared to all groups. This difference was persistent at 16 weeks. Greater improvement in patients who received the DMW product was achieved by the second injection persistent at 16 weeks.]]></description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Arthritis</subject><subject>Dietary supplements</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Hyaluronic Acid - chemistry</subject><subject>Hyaluronic Acid - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Molecular weight</subject><subject>Original Article</subject><subject>Osteoarthritis, Knee - drug therapy</subject><subject>Pain</subject><subject>Pain - drug therapy</subject><subject>Pain Measurement</subject><subject>Prospective Studies</subject><subject>Rheumatology</subject><subject>Viscosupplements - chemistry</subject><subject>Viscosupplements - therapeutic use</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kdFLZCEUxiVaamr3D9iXkB566pZ6nXu1txh2Kwj2pZ7Fq2caW69O6iXqr89hBoIgBP3k_M7nwQ-h35RcUEL6y1z3rm-qbIhoecP30IzyKqTkch_NSN-TpqVSHKKjnJ8JIUxIeoAOqWCEi76dobSI4-CCC0-4vEa8etN-SjE4g7VxNmMXcMwFok5llVxxGcclLivA_wPAFdY46WDj6N7BnmMbp8FDM3gX6m3ttYEhNiaGkqL3YHFJTvuf6MdS-wy_ducxevz752Fx29z_u7lbXN83pu1kqXODNoZTkLpj3BoxSCYHy9lS6_lAuWDadAJ6IqG1QHsyl7XANWWdsF0H7TE62_quU3yZIBc1umzAex0gTll1kom65hU8_QI-xymFOpsSgraCzAmrEN1CJsWcEyzVOrlRpzdFidqkobZpqI3cpKF47TnZGU_DCPazY_f9FWBbINdSeIL0-fL3rh9D_ZYP</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Petrella, Robert J.</creator><creator>Cogliano, Anthony</creator><creator>Decaria, Joseph</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20080801</creationdate><title>Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial</title><author>Petrella, Robert J. ; Cogliano, Anthony ; Decaria, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-31eacc41e9a624dc8b929bd42faa5b1482ac68e709e3de17059aa54a1268d66e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Arthritis</topic><topic>Dietary supplements</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Hyaluronic Acid - chemistry</topic><topic>Hyaluronic Acid - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Molecular weight</topic><topic>Original Article</topic><topic>Osteoarthritis, Knee - drug therapy</topic><topic>Pain</topic><topic>Pain - drug therapy</topic><topic>Pain Measurement</topic><topic>Prospective Studies</topic><topic>Rheumatology</topic><topic>Viscosupplements - chemistry</topic><topic>Viscosupplements - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Petrella, Robert J.</creatorcontrib><creatorcontrib>Cogliano, Anthony</creatorcontrib><creatorcontrib>Decaria, Joseph</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Petrella, Robert J.</au><au>Cogliano, Anthony</au><au>Decaria, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>27</volume><issue>8</issue><spage>975</spage><epage>981</epage><pages>975-981</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract><![CDATA[Synovial fluid in patients may differ in molecular weight depending on the presence and degree of osteoarthritis. Treatment is not directed at this relationship. Patients with osteoarthritis of the knee with resting visual analogue scale (VAS) pain of >45 mm were included in a randomized, prospective, double-blind cohort followed for 16 weeks. Patients were randomized at baseline to receive a three intra-articular injection series with one of: dual molecular weight (DMW; 580–780 kDa + 1.2 to 2.0 million Da); low molecular weight (LMW; 500–730 kDa); high molecular weight (HMW; 6 million Da); or saline placebo over 3 weeks. Patients completed baseline assessment of rest and walking VAS pain (primary efficacy variable), collection of a 5-point categorical global satisfaction score, and record of adverse events. Two-hundred and twenty-five patients (age 68 ± 8 y) were screened and 200 were randomized to one of the four groups. There were no differences at baseline between groups. At 4, 12 and 16 weeks, respectively, walking VAS pain was significantly improved in all treatment groups vs. placebo: DMW (79.6%,
p
< 0.001; 85.6,
p
< 0.001; 89.3%,
p
< 0.001); LMW (73.6%,
p
< 0.001; 76.4,
p
< 0.001; 81.3%,
p
< 0.001) and HMW (69.1%,
p
< 0.001; 81.0,
p
< 0.001; 79.1%,
p
< 0.001). Patients in the DMW group had significantly greater improvement (
p
< 0.007) in VAS walking pain by 3 weeks (following the second injection) compared to all groups. This difference was persistent at 16 weeks. Greater improvement in patients who received the DMW product was achieved by the second injection persistent at 16 weeks.]]></abstract><cop>London</cop><pub>Springer-Verlag</pub><pmid>18204873</pmid><doi>10.1007/s10067-007-0834-4</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2008-08, Vol.27 (8), p.975-981 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69282825 |
| source | Springer Nature |
| subjects | Aged Aged, 80 and over Arthritis Dietary supplements Double-Blind Method Female Humans Hyaluronic Acid - chemistry Hyaluronic Acid - therapeutic use Male Medicine Medicine & Public Health Middle Aged Molecular weight Original Article Osteoarthritis, Knee - drug therapy Pain Pain - drug therapy Pain Measurement Prospective Studies Rheumatology Viscosupplements - chemistry Viscosupplements - therapeutic use |
| title | Combining two hyaluronic acids in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T14%3A52%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combining%20two%20hyaluronic%20acids%20in%20osteoarthritis%20of%20the%20knee:%20a%20randomized,%20double-blind,%20placebo-controlled%20trial&rft.jtitle=Clinical%20rheumatology&rft.au=Petrella,%20Robert%20J.&rft.date=2008-08-01&rft.volume=27&rft.issue=8&rft.spage=975&rft.epage=981&rft.pages=975-981&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-007-0834-4&rft_dat=%3Cproquest_cross%3E2418588621%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-31eacc41e9a624dc8b929bd42faa5b1482ac68e709e3de17059aa54a1268d66e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=881380502&rft_id=info:pmid/18204873&rfr_iscdi=true |